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COMPARISON OF 30-DAY DIRECT MEDICAL COSTS OF
AZITHROMYCIN AND LEVOFLOXACIN FOR PATIENTS
HOSPITALIZED WITH COMMUNITY-ACQUIRED PNEUMONIA
Matchar DB1, Samsa GP1, Harnett J2,Wilson J2
1Duke University, Durham, NC, USA; 2Pﬁzer, Inc, New York, NY, USA
OBJECTIVES: The CAP-IN study compared two methods of
treatment for moderately to severely ill patients hospitalized with
community-acquired pneumonia: a 7–10 day course of sequen-
tial therapy with intravenous azithromycin plus intravenous cef-
triaxone followed by oral levoﬂoxacin (AZITH) versus a 7–14
day course of intravenous levoﬂoxican followed by oral lev-
oﬂoxacin (LEVO). The trial was stopped early, with n = 110 for
AZITH and n = 102 for LEVO, when similar clinical efﬁcacy
was demonstrated. We compared the 30-day direct medical costs
of the two treatments. METHODS: The primary inputs to the
economic analysis were drug dosage, hospital days and location
during the stay, and post-discharge utilization (home care, out-
patient visit, emergency department, physician ofﬁce). For each,
observed utilization was multiplied by an estimated unit price.
The sensitivity of the results to the variability of the patients in
the trial was assessed using bootstrapping. RESULTS: The dif-
ference in total cost was $2034, with 95% conﬁdence interval
$263 to $3803 (p = 0.025), in favor of AZITH. This result was
primarily due to an approximately 1.5 day difference in length
of hospital stay. CONCLUSIONS: Direct medical costs for
AZITH were $2034 less than the corresponding costs for LEVO,
the primary reason being a reduction in the length of stay.
AZITH is no more costly than LEVO, and perhaps less so. In
selecting between these drugs, physicians should consider various
factors, among them being convenience of administration and
cost.
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HOSPITAL UTILIZATION TRENDS OF HIV DISEASE IN THE
UNITED STATES, 1993 TO 2001
Zhang HF, Rajiv M, Ciuryla VT
Wyeth Research, Collegeville, PA, USA
OBJECTIVES: Advances in the treatment of HIV infection have
led to signiﬁcant improvement in clinical outcomes. Little infor-
mation is available on the long-term impact of HIV therapy on
national health care resource utilization in the US. This study is
to evaluate recent trends in hospitalization of patients with HIV
disease in the US. METHODS: Data from the Health care Cost
and Utilization Project 1993–2001 are analyzed. Hospitaliza-
tions due to HIV disease were identiﬁed using ICD-9 codes 042
and V08 as both principal diagnoses and all listed diagnoses at
discharge. National estimates of HIV hospitalizations were com-
puted based on the weights of the survey sampling structure.
RESULTS: The incidence of hospitalizations due to HIV disease
as a principal diagnosis increased dramatically from 8.9/100,000
person-years in 1993 to 57.1/100,000 person-years in 1995, then
declined signiﬁcantly to 26.1/100,000 person-years in 2001 (P =
0.0012 from regression analysis). Same trend is followed by total
annual hospital charges (in 2001 US$) due to HIV disease as the
principal diagnosis, increasing from 0.44 Billion in 1993 to $3.8
Billion in 1995 then dropping to $2.1 Billion in 2001, and its
percentage of total annual hospital charges from all causes,
increasing from 0.11% in 1993 to 0.79% in 1995, and then
declining to 0.38% in 2001. However, the incidence of hospi-
talizations with HIV disease listed in any diagnostic ﬁelds and
its percentage of total annual hospital charges show a bimodal
trend with two peaks in 1994 (126.1/100,000, 1.88%) and 1998
(99.9/100,000, 1.48%), and a nadir in 2001 (79.3/100,000,
1.18%). CONCLUSIONS: These results suggest that the number
of hospitalizations and annual hospital charges due to HIV
disease as the principal diagnosis has declined since 1995.
However, the same declining trend was not observed for hospi-
talizations listing HIV disease in any diagnostic ﬁelds.
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CLINICAL AND ECONOMIC IMPACT OF HERD IMMUNITY
ASSOCIATED WITH HEPTAVALENT PNEUMOCOCCAL
CONJUGATE VACCINATION IN CANADA
Ford MW1,Wang ECY1, Ciuryla V2
1Wyeth Canada, Markham, ON, Canada; 2Wyeth Research,
Philadelphia, PA, USA
OBJECTIVES: Since mid-2001, a heptavalent pneumococcal
conjugate vaccine (PCV-7) against 7 common pneumococcal
serotypes has been available in Canada. The purpose of this
study is to build upon existing economic evaluations and use
recent herd immunity evidence to estimate the real-world clini-
cal and economic effectiveness of PCV-7 in Canada. METHODS:
A systematic literature review was completed using Medline and
Canadian health care publications including: Canadian Journal
of Infectious Disease and Canadian Communicable Disease
Report. The search terms included: pneumococcal, costs, cost-
effectiveness, herd immunity, and incidence. Clinical and eco-
nomic impacts of adult pneumococcal disease were determined
based on epidemiologic and cost data available from the United
States and Canada. RESULTS: Three pharmacoeconomic evalu-
ations of PCV-7 in Canada have each found that routine immu-
nization would help Canada avoid substantial morbidity and
mortality, and associated health care costs and productivity
losses. Using recent effectiveness data, the reduction in adult
pneumococcal disease is estimated to save an additional $40
million from a Canadian health care perspective; suggesting the
vaccine is cost-saving. CONCLUSIONS: Herd immunity result-
ing from a universal childhood PCV-7 program will have a sub-
stantial clinical and economic impact on populations greater
than 20 years of age, thereby making PCV-7 a cost-saving inter-
vention for the Canadian health care system.
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ANTIBIOTIC PRESCRIBING RATES IN AMBULATORY CARE
SETTINGS FOR PATIENTS DIAGNOSED WITH INFLUENZA,
1997–2001
Ciesla G1, Stoddard J2, Leader S1
1MedImmune, Inc, Gaithersburg, MD, USA; 2MedImmune Vaccines, Inc,
Gaithersburg, MD, USA
OBJECTIVES: Inappropriate use of antibiotics for treating infec-
tions of viral etiology has contributed to the growing public
health problem of antibiotic resistance. Inﬂuenza has been shown
to be a major cause of febrile illness for which antibiotics are
inappropriately prescribed. The rate, pattern and cost of antibi-
otic prescribing for patients aged 5–49 diagnosed only with
inﬂuenza in the ambulatory care setting have not been docu-
mented. METHODS: Combined data from the 1997–2000
National Ambulatory Medical Care Survey and the National
Hospital Ambulatory Medical Care Survey were used to estimate
inﬂuenza visit and antibiotic prescribing rates. All visits with an
exclusive diagnosis of inﬂuenza (ICD-9 487.X) were included.
Visit costs were based on 2003 Medicare national average
allowances and drug costs for a standard agent-speciﬁc course
of treatment was calculated using average wholesale prices from
2003 Thompson MICROMEDEX Red Book. RESULTS: From
1997–2001, 6.6 million (95%CI: 5.6, 9.1) ambulatory care visits
coded with a sole diagnosis of inﬂuenza were reported for chil-
dren and adults 5–49 years; an average of 1.3 million annual
visits. Sixty-seven percent of visits were made by adults 18–49
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years at a rate of 6.9 visits/1000 persons annually (95%CI: 5.1,
8.7) compared to children 5–17 years at 8.5 visits/1000 persons
annually (95%CI: 5.6, 11.3). Visits to ofﬁce-based physicians,
hospital emergency departments and outpatient departments
accounted for 85%, 11% and 5% of visits, respectively. 
Antibiotics were prescribed at 2.5 million visits (38% of encoun-
ters) at an estimated cost of $93 million. Broad-spectrum 
antibiotics prescribed at 39% of visits where an antibiotic was
prescribed accounted for $59 million of the total cost for antibi-
otics. Combined visit and antibiotic costs for the group totaled
$441 million. CONCLUSIONS: Prescribing of antibiotics for
inﬂuenza is widespread, increases medical costs and may con-
tribute to antibiotic resistance. Increased use of vaccination 
and viral testing could reduce antibiotic use and result in cost
savings.
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COSTS AND OUTCOMES OF EXTENDED-RELEASE
CLARITHROMYCIN FOR LOWER RESPIRATORY 
TRACT INFECTIONS
Halpern MT1, Cifaldi M2, Schmier JK1
1Exponent, Alexandria,VA, USA; 2Abbott Laboratories, Abbott Park,
IL, USA
OBJECTIVES: To evaluate the costs and outcomes of extended-
release clarithromycin versus clarithromycin immediate-release
for outpatients with bacterial lower respiratory tract infections
(LRTIs, community-acquired pneumonia and acute exacerba-
tions of chronic bronchitis). METHODS: We developed a 
decision-analysis model comparing extended-release clar-
ithromycin with immediate-release for LRTIs. Treatment success
and adverse event (AE) rates were derived from weighted aver-
ages of identiﬁed published studies that included dichotomous
variables for cure vs. failure (16 immediate-release studies, 4
extended-release). Costs were standard US values. The model
included the acute antibiotic treatment period (start of ﬁrst-line
therapy through completion of second-line therapy, if applica-
ble). The model measured the proportion of patients cured on
ﬁrst- and second-line therapy, patients discontinuing due to AEs
and lack of efﬁcacy, and physician, antibiotic, and total costs per
episode. RESULTS: More patients achieved clinical cure with
clarithromycin extended-release (83.9%) than with clar-
ithromycin immediate-release (72.8%); AE discontinuation rates
were lower for the extended-release group (2.4% versus 4.9%
for the immediate-release group). Total costs with clarithromycin
extended-release were $32 (16%) less than total costs for imme-
diate-release. Sensitivity analyses indicated that the model is
robust to changes in cure and AE discontinuation rates within
reasonable ranges. Incorporating greater treatment adherence for
extended-release (once-daily) versus immediate-release (twice-
daily) therapy resulted in greater cost savings for clarithromycin
extended-release. CONCLUSIONS: Clarithromycin extended-
release is cost saving compared with clarithromycin immediate-
release for LRTIs, using base-case results. The model did not
include hospitalization, which is uncommon in mild to moder-
ate LRTIs; addition of hospitalizations is likely to demonstrate
additional costs savings with clarithromycin extended-release.
These differences in clinical and economic results are important
in that extended-release therapy can lead to improved patient
outcomes with decreased costs. Further research is needed to
determine the cause and impacts of these differences in efﬁcacy
and tolerability.
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MENINGOCOCCAL VACCINE IN PORTUGAL—A COST-
EFFECTIVENESS ANALYSIS
Gouveia M1, Borges M2,Tavares L2, Portugal R2
1Universidade Católica Portuguesa, Lisbon, Portugal; 2Faculdade de
Medicina da Universidade de Lisboa, Lisboa, Portugal
OBJECTIVE: To do a cost-effectiveness analysis of the intro-
duction of meningococcal vaccine type C (NeisVac-CTM) in Por-
tugal. METHODS: Model: The study compared vaccine with no
vaccination for a cohort of 100.000 for lifetime using a Markov
model. Scenarios for age of vaccine administration: children with
less than one year of age, children with one year of age and chil-
dren with two years of age. The outcomes measured were avoid-
able cases, avoidable death, avoidable disability and avoidable
years of life lost. RESULTS: For the case base studied the cost
per year of life gained (or lost year of prevented life) for the
NeisVac-CTM was 6372€ for vaccination administer after the ﬁrst
year of life and of 12,635€ for vaccination administer during the
ﬁrst year of life. Difference is explained by the need of two doses
of vaccine during the ﬁrst year of life and only one for the other
scenario. These costs includes the cost of vaccines, the effect and
consequences of vaccines in the consumption of resources of the
health system (hospital, outpatients, medicines, exams, etc.),
direct costs for the State other than of the health system (support
of the Social Welfare and the deﬁcient ones) and the indirect costs
generated by the effect of the disease in the productivity lost by
the families in the case of children or of the self in the case of
disease while in active labor age. Sensitivity analysis showed the
robustness of these values. CONCLUSIONS: Compared with
other interventions routinely done by the National Health
Service the administration of the of the NeisVac-CTM it can be
considered cost-effective for the Portuguese population.
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THE IMPACT OF PHYSICIAN PROFILING ON ANTIBIOTIC
COST AND UTILIZATION
Ramos K1,Teng DG1,Ara SB2,Tam JY1, Keeling F2, Finch MJ1
1Health Net, Oakland, CA, USA; 2Health Net, Woodland Hills, CA,
USA
OBJECTIVE: This study examines the beneﬁt of physician pro-
ﬁling on cost and utilization of antibiotics. METHODS: General
Practitioners, Family Practitioners, Internists and Pediatricians
were sent an education tool regarding the appropriate use of
antibiotics for the treatment of respiratory illnesses for the
2000–01, 2001–02 and 2002–03 seasons. Physicians who pre-
scribed greater than 60 antibiotics in the previous year also
received a proﬁle of their ﬁrst line antibiotic use. The average
ingredient cost per prescription for proﬁled vs. non-proﬁled
physicians was used to determine the impact of physician pro-
ﬁling on antibiotic prescribing behavior. Physicians were also
surveyed during the 2000/01 season on the usefulness of the edu-
cation tool and the proﬁle. RESULTS: Approximately seventeen
thousand physicians were targeted for each season. The ingredi-
ent cost per prescription for ﬁrst line antibiotics was signiﬁcantly
lower for proﬁled (N = 3286) vs. non proﬁled physicians in all
three seasons: $5.19 vs. $5.31 (p < 0.0001) for season 1; $6.29
vs. $6.57 (p < 0.0001) for season 2; and $8.39 vs. $8.57 (p =
0.0003) for season 3. The ingredient cost per prescription was
also lower for second line antibiotics in the proﬁled vs. non-pro-
ﬁled groups for each consecutive season: $55.35 vs. $67.09 (p =
0.057), $56.53 vs. $57.35 (p < 0.0001), and $56.58 vs. $57.22
(p = 0.0001), respectively. Out of the 4.1% of physicians who
responded to the program survey, 84% agreed that the infor-
mation in the education tool was informative and useful. Seventy
